Cargando…

Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study

PURPOSE: We conducted a first-in-human, dose-escalation study, to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and activity of TAK-931, a cell division cycle 7 inhibitor, in Japanese patients with advanced solid tumors. EXPERIMENTAL DESIGN: Patients ages ≥20 years received...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuboki, Yasutoshi, Shimizu, Toshio, Yonemori, Kan, Kojima, Takashi, Kondo, Shunsuke, Koganemaru, Shigehiro, Iwasa, Satoru, Harano, Kenichi, Koyama, Takafumi, Lu, Vickie, Zhou, Xiaofei, Niu, Huifeng, Yanai, Tomoko, Garcia-Ribas, Ignacio, Doi, Toshihiko, Yamamoto, Noboru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035389/ https://www.ncbi.nlm.nih.gov/pubmed/36970056 http://dx.doi.org/10.1158/2767-9764.CRC-22-0277

Ejemplares similares

Population Pharmacokinetics of TAK‐931, a Cell Division Cycle 7 Kinase Inhibitor, in Patients With Advanced Solid Tumors
por: Zhou, Xiaofei, et al.
Publicado: (2021)

Assessment of Effects of Investigational TAK‐931, an Oral Cell Division Cycle 7 Kinase Inhibitor on the QTc Intervals in Patients With Advanced Solid Tumors
por: Zhou, Xiaofei, et al.
Publicado: (2022)

A phase 1 open-label study to assess the relative bioavailability of TAK-931 tablets in reference to powder-in-capsule in patients with advanced solid tumors
por: Steeghs, Neeltje, et al.
Publicado: (2022)

A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies
por: Shimizu, Toshio, et al.
Publicado: (2021)

Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies
por: Shimizu, Toshio, et al.
Publicado: (2022)

Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor
por: Iwai, Kenichi, et al.
Publicado: (2019)

Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study
por: Doi, Toshihiko, et al.
Publicado: (2021)

First‐in‐human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors
por: Kondo, Shunsuke, et al.
Publicado: (2021)

First‐in‐human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors
por: Koyama, Takafumi, et al.
Publicado: (2020)

Practical consideration for successful sequential tumor biopsies in first-in-human trials
por: Koyama, Takafumi, et al.
Publicado: (2022)

A phase 1 trial of xentuzumab, an IGF‐neutralizing antibody, in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2022)

931. Telemedicine for the Treatment of Hepatitis C: A Systematic Review and Meta-Analysis
por: De Gijsel, David, et al.
Publicado: (2018)

SUN-931 Characterization of an Ovarian Steroid Cell Tumor in a VHL Patient
por: Nocito, Marta Claudia, et al.
Publicado: (2020)

Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials
por: Nagatani, Yoshiaki, et al.
Publicado: (2016)

Ocular toxicity of investigational anti-cancer drugs in early phase clinical trials
por: Takamizawa, Shigemasa, et al.
Publicado: (2022)

931. Congestive Heart Failure in Persons Living with HIV: Are we providing standard of care?
por: Chowdhury, Salil K, et al.
Publicado: (2020)

Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours
por: Ebata, Takahiro, et al.
Publicado: (2019)

The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study
por: Yonemori, Kan, et al.
Publicado: (2021)

A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors
por: Yamamoto, Noboru, et al.
Publicado: (2021)

A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites
por: Matsumoto, Hiroshi, et al.
Publicado: (2018)

Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors
por: Kawazoe, Akihito, et al.
Publicado: (2020)

931. Host PFKFB3-dependent glycolytic reprogramming as a broad-spectrum antiviral strategy
por: Yuan, Shuofeng, et al.
Publicado: (2023)

p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumab
por: Fukuoka, Shota, et al.
Publicado: (2023)

Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study
por: Shimizu, Toshio, et al.
Publicado: (2022)

A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer
por: Kawazoe, Akihito, et al.
Publicado: (2015)

Phase I study of the irreversible fibroblast growth factor receptor 1–4 inhibitor futibatinib in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2022)

First results from the high-brightness X-ray spectroscopy beamline 9.3.1 at ALS
por: Ng, W, et al.
Publicado: (1995)

Benign Tumors of the Esophagus: A Histopathologic Study of 49 Cases among 931 Consecutive Esophageal Biopsies
por: Terada, Tadashi
Publicado: (2009)

MDM2 promoter del1518 polymorphism and cancer risk: evidence from 22,931 subjects
por: Hua, Wenfeng, et al.
Publicado: (2017)

First‐in‐human study of ONO‐4578, an antagonist of prostaglandin E(2) receptor 4, alone and with nivolumab in solid tumors
por: Iwasa, Satoru, et al.
Publicado: (2022)

Run 931 - Physics, A significant reduction of beam-beam interaction during 31 GeV/c acceleration
por: Koutchouk, Jean-Pierre
Publicado: (1978)

P931: PROSPECTIVE OBSERVATIONAL MULTICENTER STUDY OF GAUCHER DISEASE PREVALENCE IN PATIENTS AFFECTED BY MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE
por: Giuffrida, G., et al.
Publicado: (2022)

Correction: Gladkikh et al. Epidemiological Features of COVID-19 in Northwest Russia in 2021. Viruses 2022, 14, 931
por: Gladkikh, Anna, et al.
Publicado: (2023)

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer
por: Mishima, Saori, et al.
Publicado: (2019)

Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study
por: Naito, Yoichi, et al.
Publicado: (2021)

TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma
por: Teramachi, Jumpei, et al.
Publicado: (2020)

Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma
por: Mishima, Saori, et al.
Publicado: (2018)

La reforma de la fracción lV del artículo 931 de la ley federal del trabajo.
por: Pulido Castillo, Margarita
Publicado: (1992)

P931: ISATUXIMAB IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH ULTRA-HIGH-RISK CYTOGENETICS: ICARIA-MM AND IKEMA SUBGROUP ANALYSIS
por: Moreau, Philippe, et al.
Publicado: (2023)

Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors
por: Sato, Jun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vmnd7384deej761vt16a56bouf